GB0905641D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0905641D0
GB0905641D0 GBGB0905641.7A GB0905641A GB0905641D0 GB 0905641 D0 GB0905641 D0 GB 0905641D0 GB 0905641 A GB0905641 A GB 0905641A GB 0905641 D0 GB0905641 D0 GB 0905641D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0905641.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus AS
Original Assignee
Serodus AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus AS filed Critical Serodus AS
Priority to GBGB0905641.7A priority Critical patent/GB0905641D0/en
Publication of GB0905641D0 publication Critical patent/GB0905641D0/en
Priority to MX2011010215A priority patent/MX2011010215A/en
Priority to PCT/GB2010/000656 priority patent/WO2010112865A1/en
Priority to US13/262,356 priority patent/US20120094989A1/en
Priority to CA2757106A priority patent/CA2757106A1/en
Priority to EP10712115A priority patent/EP2414331A1/en
Priority to JP2012502774A priority patent/JP2012522758A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0905641.7A 2009-04-01 2009-04-01 Compounds Ceased GB0905641D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0905641.7A GB0905641D0 (en) 2009-04-01 2009-04-01 Compounds
MX2011010215A MX2011010215A (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds.
PCT/GB2010/000656 WO2010112865A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
US13/262,356 US20120094989A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
CA2757106A CA2757106A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
EP10712115A EP2414331A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
JP2012502774A JP2012522758A (en) 2009-04-01 2010-04-01 5-HT receptor modulating compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905641.7A GB0905641D0 (en) 2009-04-01 2009-04-01 Compounds

Publications (1)

Publication Number Publication Date
GB0905641D0 true GB0905641D0 (en) 2009-05-13

Family

ID=40672123

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0905641.7A Ceased GB0905641D0 (en) 2009-04-01 2009-04-01 Compounds

Country Status (7)

Country Link
US (1) US20120094989A1 (en)
EP (1) EP2414331A1 (en)
JP (1) JP2012522758A (en)
CA (1) CA2757106A1 (en)
GB (1) GB0905641D0 (en)
MX (1) MX2011010215A (en)
WO (1) WO2010112865A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (en) 2010-04-22 2015-12-09 弗特克斯药品有限公司 Pharmaceutical compositions and administrations thereof
JP6543268B2 (en) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Pharmaceutical composition for treating a disease mediated by a cystic fibrosis transmembrane conductance regulator
KR102630416B1 (en) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CN114222730B (en) 2019-08-14 2024-09-10 吉利德科学公司 Compounds for inhibiting α4β7 integrin
CN110950843B (en) * 2019-11-28 2022-12-27 广东东阳光药业有限公司 Substituted benzamide derivatives and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
ATE266033T1 (en) * 1992-03-12 2004-05-15 Smithkline Beecham Plc N-(1-NBUTYL-4-PIPERIDYL)METHYL -3,4-DIHYDRO-2H- 1,3 OXAZINO 3,2-A INDOL-10-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EP0641198A1 (en) * 1992-05-23 1995-03-08 Smithkline Beecham Plc Medicaments for the treatment of anxiety
ES2103675B1 (en) * 1995-01-10 1998-07-01 Almirall Lab NEW PIPERIDINES REPLACED.
DE602004025508D1 (en) * 2003-12-23 2010-03-25 Serodus As MODULATORS OF PERIPHERAL 5-HT RECEPTORS
WO2007007072A1 (en) 2005-07-07 2007-01-18 Bio-Medisinsk Innovasjon As 5-htx modulators
WO2007149929A1 (en) 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders

Also Published As

Publication number Publication date
JP2012522758A (en) 2012-09-27
CA2757106A1 (en) 2010-10-07
EP2414331A1 (en) 2012-02-08
MX2011010215A (en) 2012-02-28
US20120094989A1 (en) 2012-04-19
WO2010112865A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
IL213992A0 (en) Pro-neurogenic compounds
IL215147A0 (en) Compounds
GB0907425D0 (en) Compounds
EP2393493A4 (en) Compounds
GB0918249D0 (en) Compounds
GB0907515D0 (en) Compounds
IL213019A0 (en) Azaazulene compounds
GB0914856D0 (en) Compounds
GB0919194D0 (en) Compounds
GB0915892D0 (en) Compounds
GB0922302D0 (en) Compounds
GB0909671D0 (en) Compounds
GB0903493D0 (en) New compounds
IL217049A0 (en) 3-phenoxymethylpyrrolidine compounds
GB0919594D0 (en) Compounds
GB0915519D0 (en) Ntithrombotic compounds
GB0909672D0 (en) Compounds
GB0911000D0 (en) Compounds
EP2443115A4 (en) Compounds
GB0919263D0 (en) Compounds
GB0906378D0 (en) Compounds
GB0910675D0 (en) Compounds
GB0915685D0 (en) Compounds
GB0903492D0 (en) Compounds
GB0904746D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)